Lerociclib: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer

Scientific rationale and therapeutic potential

Lerociclib is a potent and selective oral CDK4/6 inhibitor designed to block the proliferation of breast-cancer cells and induce tumor-cell death when combined with a selective estrogen receptor degrader (SERD), such as Faslodex®. Lerociclib has the potential to be best-in-class versus other oral CDK4/6 inhibitors.

Preclinical and clinical results (see: Publications)

G1 is recruiting patients for a Phase 1b/2a trial in ER+, HER2- breast cancer

G1T38-02 Trial  
  • ER+, HER2- breast cancer, after endocrine therapy failure
  • multi-center, open-label
  • lerociclib + Faslodex┬«
  • approximately 80 patients
  • ClinicalTrials.gov identifier: NCT02983071


Click here for printable version of our lerociclib ER+ HER2- breast cancer clinical trial fact sheet